Enfusion, Inc. (NYSE:ENFN) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lowered its stake in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,341,561 shares of the company's stock after selling 676,290 shares during the period. Vanguard Group Inc. owned 2.60% of Enfusion worth $34,418,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company's stock worth $9,770,000 after purchasing an additional 70,367 shares during the last quarter. Wellington Management Group LLP lifted its position in Enfusion by 6.7% during the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock valued at $9,265,000 after acquiring an additional 61,032 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Enfusion by 612.4% in the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company's stock valued at $1,974,000 after acquiring an additional 178,821 shares in the last quarter. Barclays PLC grew its holdings in Enfusion by 251.4% in the third quarter. Barclays PLC now owns 86,039 shares of the company's stock worth $817,000 after purchasing an additional 61,554 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Enfusion during the fourth quarter worth $144,000. Institutional investors own 81.05% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on ENFN shares. Piper Sandler upped their target price on Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a research report on Monday, December 23rd. William Blair restated a "market perform" rating on shares of Enfusion in a report on Monday, January 13th.

Insider Buying and Selling at Enfusion

In other news, CEO Oleg Movchan sold 2,790 shares of Enfusion stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total transaction of $32,029.20. Following the completion of the transaction, the chief executive officer now directly owns 643,299 shares of the company's stock, valued at $7,385,072.52. The trade was a 0.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bronwen Bastone sold 3,126 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $35,573.88. Following the sale, the insider now directly owns 221,875 shares in the company, valued at $2,524,937.50. This trade represents a 1.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 66,223 shares of company stock valued at $754,778. 36.44% of the stock is owned by insiders.

Enfusion Price Performance

ENFN traded down $0.01 on Friday, reaching $10.80. 2,461,878 shares of the stock were exchanged, compared to its average volume of 632,273. The company's 50-day moving average price is $11.08 and its 200 day moving average price is $10.41. The firm has a market capitalization of $1.39 billion, a PE ratio of 269.94, a PEG ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80.

Enfusion (NYSE:ENFN - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). The business had revenue of $52.94 million for the quarter, compared to analysts' expectations of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. As a group, equities analysts forecast that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.